GLP1RA medications linked to behavioral side effects in type 2 diabetes and obesity
The Evolving Role of GLP1RA in Diabetes Management and Mental Health As the use of GLP1RA—glucagon-like peptide 1 receptor agonists—grows in managing type 2 diabetes and obesity, there is increasing interest in their behavioral side effects. Recent research published in Diabetes, Obesity and Metabolism offers an in-depth look at these potential side effects and offers … Read more